



PRESS RELEASE

04/03/2021

NovaMedica R&D Centre Released the First Commercial Batch of Avifavir Antiviral Drugs

The NovaMedica Innotech Technology Centre (a subsidiary of the NovaMedica pharmaceutical company, an investment project of RUSNANO) announces the release of the first commercial batch of Avifavir®, an antiviral drug, as part of a partnership with Kromis LLC, a joint venture of the Russian Direct Investment Fund (RDIF) and ChemRar Group.

The production level of Avifavir at NovaMedica Innotech will be 100,000 packs per month.

“Technology transfer was carried out efficiently and promptly thanks to hard work of the R&D division team and a well-suited production equipment profile. The first commercial series of the drug is at present ready for shipment,” **Alexander Rudko**, General Director of NovaMedica Innotech Technology Centre commented.

Technological lines used for manufacturing Avifavir pills are certified in accordance with the GMP requirements. All NovaMedica Innotech Technology Centre’s pharmaceutical quality system processes ensure the fabrication of a quality product. Quality control is conducted at each stage of the technological process, making it possible to assess the product’s compliance with the requirements of specifications and regulatory documents.

***The RUSNANO Group** includes the RUSNANO Joint Stock Company, the RUSNANO Management Company and the Fund for Infrastructure and Educational Programs. Thanks to RUSNANO’s investments, there are currently 126 factories and R&D Centers opened in 38 regions in Russia.*

Currently, the Russian Government is reconfiguring the system of development institutions, which provides for the integration of RUSNANO into the management scope of VEB.RF. Based on VEB, a centralized investment unit is being created to implement projects that contribute to national development goals. The VEB Group’s priority is to consolidate public and private investment resources for the country’s breakthrough development, improve quality, and create comfortable conditions for people’s lives.

More information can be found at en.rusnano.com

Contact details: 10A, Prospect 60-Ietia Oktyabrya, Moscow, 117036 Tel.: +7 (495) 988-5677, Fax: +7 (495) 988-5399, e-mail: press@rusnano.com.